Used for its anti-parasite activity.
- Impairment neuromuscular transmission
Aminoglycoside ototoxicity is associated with a genetic susceptibility in a third to a half of all cases. Most commonly mitochondrial – shows bacterial origin. Screening patients likely to need repeated courses eg CFs, chemotherapy patients, preterm neonates is feasible, but cost:benefit ratio? Consider costs of deafness, cochlear implant etc.
- Enhanced ototoxicity with ototoxic diuretics eg furosemide.